Nuclear Energy Stock SMR Is Trading Under $10: Bargain Buy or Value Trap?

NuScale Power’s stock has collapsed—down 75% in one year and trading below $10 after an all-time high of $57.42 (Oct. 16, 2025), including a 61% slump in the last quarter of 2025. The article attributes the selloff to weak operating progress plus class-action lawsuits and the largest shareholder (Fluor) cashing out, alongside a lack of binding customer contracts despite regulatory progress for its 77 MWe SMR module design. NuScale also does not expect to deliver its first NPMs until 2031 at the earliest, keeping commercialization risk elevated even as AI-driven power demand highlights the longer-term market need.

Analysis

The market is pricing AI power scarcity as if it automatically converts into SMR revenue, but the real bottleneck is financing and off-take. A pre-revenue reactor story with no binding customer commit can look cheap on price alone while still being expensive on probability-weighted cash flow, especially if another equity raise is needed before any commercial cash arrives.

Second-order winners are the parts of the power stack that can monetize the buildout without first-of-a-kind execution risk: grid equipment, gas turbines, EPCs, and fuel-cycle names. By contrast, SMR is a single-threaded story, so any delay, lawsuit, or governance headline hits both the multiple and the funding path; that makes it much more fragile than broader nuclear or power-infrastructure exposure.

The catalyst path is binary over the next 1-3 months: a credible, binding off-take agreement or project-finance framework can force a squeeze, while continued no-contract status should keep the stock under pressure. Over 6-18 months, the key falsifier for the short thesis is evidence the first module timeline is pulled forward meaningfully or funded without dilution; absent that, this behaves like a long-dated call option rather than a utility substitute.

Key Decisions for Investors

• Short SMR into any strength / use 3-6 month put spreads to define risk; thesis works if the market keeps re-rating the name toward optionality rather than commercialization. Falsifier: binding PPA or government-backed financing announcement.
• Pair trade: long a cleaner nuclear/fuel-cycle beneficiary such as CCJ or BWXT against short SMR for 1-3 months. This expresses the view that the market will favor monetizable nuclear exposure over pre-revenue reactor IP.
• Avoid naked shorts in FLR solely on this headline; if you want to express sponsor skepticism, wait for a second wave of NuScale-related governance or dilution news before acting.
• Set an alert for any equity raise, convert, or milestone-payment amendment at SMR over the next 90 days; that is the most likely downside accelerator and would materially weaken the bull case.
• If forced to own nuclear exposure, rotate toward infrastructure/utility proxies rather than SMR until there is a binding customer and a firmer delivery timetable; the risk/reward in SMR remains unfavorable below $10 without commercialization proof.